Lupin Limited, a global leader in the pharmaceutical industry, has announced plans to integrate Honeywell’s Solstice® Air (HFO-1234ze(E) cGMP) propellant into the development of next-generation inhalers. This partnership aims to enhance respiratory care for patients suffering from asthma and chronic obstructive pulmonary disease (COPD) while significantly reducing the environmental impact of inhaler technologies.
Solstice Air, a cutting-edge, non-flammable propellant, offers an alternative to traditional hydrofluorocarbon (HFC)-based options, helping to decrease greenhouse gas emissions by up to 99.9%. This new initiative aligns with Lupin’s commitment to minimizing the carbon footprint of its respiratory treatments, all while continuing to deliver effective care to patients.
Lupin plans to become the first pharmaceutical company in India to utilize Honeywell’s Solstice Air as a large-scale propellant in pressurized metered-dose inhalers (pMDIs). By adopting this innovative propellant, Lupin takes a major step toward reducing carbon emissions and advancing sustainable healthcare solutions.
Vinita Gupta, CEO of Lupin, stated, “Our collaboration with Honeywell reflects our dedication to providing high-quality treatments while ensuring a healthier and more sustainable future for both our patients and communities globally. By incorporating Solstice Air, we are not only improving patient care but also reducing the environmental footprint of our respiratory solutions.”
Ashish Modi, President of Honeywell India, added, “Solstice Air is integral to ensuring that Lupin’s inhalers deliver safe and effective treatments while also leveraging the latest technological advancements to minimize harmful greenhouse gas emissions. Honeywell is committed to advancing innovations that enhance healthcare efficacy and promote environmentally responsible practices.” The partnership details are still under negotiation, with both companies working towards finalizing the terms.
Honeywell is a global leader in technology and innovation, operating across industries such as aerospace, industrial automation, energy, and sustainability. The company is committed to addressing complex challenges through its cutting-edge solutions, enhancing safety, security, and sustainability worldwide.
Lupin Limited, headquartered in Mumbai, India, is a major player in the global pharmaceutical industry, offering a wide range of products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin is recognized for its strength in therapy areas such as respiratory care, cardiovascular, anti-diabetic, and more. The company operates 15 manufacturing facilities and seven research centers globally, employing over 23,000 professionals to drive its mission of improving patient health outcomes through advanced healthcare solutions.
